Basic Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Jun 14, 2019; 25(22): 2763-2775
Published online Jun 14, 2019. doi: 10.3748/wjg.v25.i22.2763
Table 1 Clinicopathological characteristics of the study population
Tissue samples
Serum samplesHealthy controls
(n = 25)
Gender
Male155726
Female103714
Age
Mean ± SD60 ± 759 ± 759 ± 8
Median (range)61 (45-72)60 (40-74)60 (41-74)
Tumor size (cm)
<51959
≥5635
TNM stage
I1318
II921
III342
IV013
Differentiation
Well and moderate1350
Poor1244
Invasion depth
T139
T2732
T31235
T4318
Lymph node metastasis
Positive1850
Negative744
Table 2 Association of serum HOXA11-AS with clinicopathological characteristics in patients with gastric cancer
Clinical featureCasesSerum HOXA11-ASP-value
Gender0.824
Male570.345 ± 0.104
Female370.349 ± 0.091
Age (yr)0.304
<60380.337 ± 0.111
≥60560.355 ± 0.089
Tumor size (cm)0.001
<5590.320 ± 0.094
≥5350.391 ± 0.092
TNM stage0.001
I and II390.250 ± 0.073
III and IV550.415 ± 0.040
Differentiation0.934
Well and moderate500.346 ± 0.112
Poor440.347 ± 0.084
Invasion depth0.867
T1 and T2410.348 ± 0.100
T3 and T4530.345 ± 0.099
Lymph node metastasis0.011
Positive500.377 ± 0.088
Negative440.312 ± 0.100
Table 3 Univariate and multivariate survival analyses of 94 gastric cancer patients
VariableUnivariate analysis
Multivariate analysis
HR95%CIP-valueHR95%CIP-value
Gender (Male vs Female)1.3100.749-2.2910.344- - -- - -- - -
Age (yr) (<60 vs ≥60)0.9870.560-1.7390.963- - -- - -- - -
Tumor size (cm) (<5 vs ≥5)0.5270.301-0.9240.0250.8160.442-1.5080.516
TNM stage (I + II vs III + IV)0.1950.092-0.4170.0010.4370.125-1.5220.193
Differentiation (Well and moderate vs Poor)0.9230.529-1.610.779- - -- - -- - -
Invasion depth (T1 + T2 vs T3 vs T4)1.0500.601-1.8360.863- - -- - -- - -
Lymph node metastasis (Positive vs Negative)0.6670.379-1.1760.162- - -- - -- - -
Serum HOXA11-AS (High vs Low)0.2010.104-0.3850.0010.3380.115-0.9890.048